Tags

Type your tag names separated by a space and hit enter

The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis.
Neuropsychopharmacology 2004; 29(8):1558-72N

Abstract

Recent advances in the understanding of brain cannabinoid receptor function have renewed interest in the association between cannabinoid compounds and psychosis. In a 3-day, double-blind, randomized, and counterbalanced study, the behavioral, cognitive, and endocrine effects of 0, 2.5, and 5 mg intravenous delta-9-tetrahydrocannabinol (Delta-9-THC) were characterized in 22 healthy individuals, who had been exposed to cannabis but had never been diagnosed with a cannabis abuse disorder. Prospective safety data at 1, 3, and 6 months poststudy was also collected. Delta-9-THC (1) produced schizophrenia-like positive and negative symptoms; (2) altered perception; (3) increased anxiety; (4) produced euphoria; (5) disrupted immediate and delayed word recall, sparing recognition recall; (6) impaired performance on tests of distractibility, verbal fluency, and working memory (7) did not impair orientation; (8) increased plasma cortisol. These data indicate that Delta-9-THC produces a broad range of transient symptoms, behaviors, and cognitive deficits in healthy individuals that resemble some aspects of endogenous psychoses. These data warrant further study of whether brain cannabinoid receptor function contributes to the pathophysiology of psychotic disorders.

Links

  • Publisher Full Text

    • Authors+Show Affiliations

    D'Souza DC
    Schizophrenia Biological Research Center, VA Connecticut Healthcare System, West Haven, CT 06516, USA. deepak.dsouza@yale.edu
    Perry E
    No affiliation info available
    MacDougall L
    No affiliation info available
    Ammerman Y
    No affiliation info available
    Cooper T
    No affiliation info available
    Wu YT
    No affiliation info available
    Braley G
    No affiliation info available
    Gueorguieva R
    No affiliation info available
    Krystal JH
    No affiliation info available

    MeSH

    AdultAnxietyArousalAttentionBehaviorCognitionDose-Response Relationship, DrugDouble-Blind MethodDronabinolFemaleHallucinogensHemodynamicsHumansHydrocortisoneInjections, IntravenousMaleMemory, Short-TermMental RecallPanicProlactinPsychiatric Status Rating ScalesPsychometricsPsychoses, Substance-InducedSpeechVerbal Learning

    Pub Type(s)

    Clinical Trial
    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't
    Research Support, U.S. Gov't, Non-P.H.S.
    Research Support, U.S. Gov't, P.H.S.

    Language

    eng

    PubMed ID

    15173844

    Citation

    D'Souza, Deepak Cyril, et al. "The Psychotomimetic Effects of Intravenous Delta-9-tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis." Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, vol. 29, no. 8, 2004, pp. 1558-72.
    D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29(8):1558-72.
    D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y. T., ... Krystal, J. H. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, 29(8), pp. 1558-72.
    D'Souza DC, et al. The Psychotomimetic Effects of Intravenous Delta-9-tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis. Neuropsychopharmacology. 2004;29(8):1558-72. PubMed PMID: 15173844.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. AU - D'Souza,Deepak Cyril, AU - Perry,Edward, AU - MacDougall,Lisa, AU - Ammerman,Yola, AU - Cooper,Thomas, AU - Wu,Yu-Te, AU - Braley,Gabriel, AU - Gueorguieva,Ralitza, AU - Krystal,John Harrison, PY - 2004/6/3/pubmed PY - 2004/9/9/medline PY - 2004/6/3/entrez SP - 1558 EP - 72 JF - Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology JO - Neuropsychopharmacology VL - 29 IS - 8 N2 - Recent advances in the understanding of brain cannabinoid receptor function have renewed interest in the association between cannabinoid compounds and psychosis. In a 3-day, double-blind, randomized, and counterbalanced study, the behavioral, cognitive, and endocrine effects of 0, 2.5, and 5 mg intravenous delta-9-tetrahydrocannabinol (Delta-9-THC) were characterized in 22 healthy individuals, who had been exposed to cannabis but had never been diagnosed with a cannabis abuse disorder. Prospective safety data at 1, 3, and 6 months poststudy was also collected. Delta-9-THC (1) produced schizophrenia-like positive and negative symptoms; (2) altered perception; (3) increased anxiety; (4) produced euphoria; (5) disrupted immediate and delayed word recall, sparing recognition recall; (6) impaired performance on tests of distractibility, verbal fluency, and working memory (7) did not impair orientation; (8) increased plasma cortisol. These data indicate that Delta-9-THC produces a broad range of transient symptoms, behaviors, and cognitive deficits in healthy individuals that resemble some aspects of endogenous psychoses. These data warrant further study of whether brain cannabinoid receptor function contributes to the pathophysiology of psychotic disorders. SN - 0893-133X UR - https://www.unboundmedicine.com/medline/citation/15173844/The_psychotomimetic_effects_of_intravenous_delta_9_tetrahydrocannabinol_in_healthy_individuals:_implications_for_psychosis_ L2 - http://dx.doi.org/10.1038/sj.npp.1300496 DB - PRIME DP - Unbound Medicine ER -